Uehara S, Hirayama A
Department of Internal Medicine, Tonan Hospital, Sapporo, Japan.
Arzneimittelforschung. 1989 Dec;39(12):1531-4.
The antiplatelet effect of cilostazol (OPC-13013) was investigated by means of both in vitro and in vivo examinations. With the in vitro tests, cilostazol showed an inhibitive effect approximately 10 times greater than trapidil as a result of comparative examinations of the platelet aggregation inhibitive effect using trapidil as the control. In the in vivo tests, which were conducted to observe the platelet aggregation inhibitive effect as a result of oral administration of cilostazol at 100 mg/d for 4 weeks to patients with stable cerebral vascular diseases, a significant decrease in aggregation was recognized.
